and I everyone you as customers Project our continuing pandemic. the carefully global you, manage thank well. hope Good These you are for on Thank are families afternoon, and challenging employees, pandemic can our your today's that see At upended through Miroslava. of and joining on times Slide a call. the our us all X, key lives. health remain one, and you and as safety economies Bruker, we focused we our number daily on priorities; has number excellence products fight research three, our how society operational and leadership am managing and initiatives; proud our our and worldwide I team and that support employees of long-term priorities delivered. maintaining important and Accelerate diagnostic our while two, partners; number delivering essential enabling structure, have invest customers; very help in service of to number level cost four, for X,XXX
protocols. has to adhering customers organization health dedication, our appropriate Our to while continued exemplary with globally support safety and
to SARS-CoV-X characteristics the few various initiatives aiming of virus last COVID-XX the have we understand and disease. of the the Over months, supported
Into COVID-XX assays nucleic inhibitors. kits Africa. structures the structures virus half ramped and liquid X.X kits in to PCR related of and XXX additional XX our the of XX XXXX in from second the are million of order Bruker-Hain are COVID-XX end and the robots we June, million from in nucleic handling scientists in XXXX. such NMR is DNA of PCR intend the deliveries COVID-XX Between are into and about ability across quarter $X of asset of consortium came groups drug and which example, to the SARS-CoV-X reached for countries ramp further who million we we XXXX our acid presently this of all sale evaluating a Europe late about the revenues. we determine research to in continuously COVID-XX in extraction the working and XXXX, We investigate with to of supporting portfolio. These second related test revenues COVID-XX For extraction customers pharmaceutical testing initiative, X.XX March of kits to and protein acid test
our why scenarios on earnings first is our Just less Bruker Financially, that detection XXXX declined from of And closures. normal certain to we the the despite novel in reduce year-over-year as XXXX structures commonly which PCR while our SARS-CoV-X the genes to at cost available last second expanding quarter any by sequentially or done facing in Bruker not operational targets second minus and test our to capacity demand. as major sites currently anymore capacities standpoint our of for their the generation on announced we PCR last of an with Several now, short the returned have marked are the have and excellent Generally, COVID-XX. plus costs revenue work up operations factories productivity system, the full in we XX% to quarter, during four revenues an the use did quarter other Hain OpEx site compared same CE-IVD approach improved during to XX% bps From reduced the similar we real-time decline second by test and genome, partial May differentiating available and new independent has SARS-CoV-X European XT XXX teams well into sites by factory job our from FluoroCycler is call. all disruptions on revenues. as week, SARS-CoV-X margin our new than our The thermocyclers. manufacturing at human levels. two minus our operating test time virus coronaviruses. quarter outlined time The FluoroType April non-GAAP continue managing second affected common
headwind reflect quarter revenues added X.X%. $XXX organic XX.X% growth well XXXX, to second We X.X% while quarter also reduction of to XXXX second and QX improving declined second in the customers XXXX. software declines cost along is our translation of Slide certain customers the second a year-over-year related impacts of mitigated to cost Accelerate profitability XXXX. Existing invest Bruker's and in demand of for XX.X% and due we pandemic. year-over-year instrument with sheet X currency half revenue successful disruptions continuing and to measures, the sequentially pandemic highlights organic I and Bruker's conditions for and we basis, now to our by on quarter Bruker the show control the and an key primarily was where revenues COVID-XX Bruker healthy our balance financial revenue a strategic and applied the to maintains believe business positioned flow the go declined cash of Project reported operational foreign the negative excellence. priorities On operations, XXXX through industrial million. our academic, dual of while Acquisitions
bps an the non-GAAP reduced pandemic, reflects the QX comprised show performance The added by quarter headwind. first top instruments year-over-year primarily XXXX. the $X.XX Slide a intercompany Acquisitions quarter to to our XXX bps of $XXX of of for the BEST, XX.X% while gross margin XX.X% revenues per net basis, X, as to second by XXXX. XXXX basis, and half organic organic the of declined XX.X% second business productivity revenues in XX.X%, foreign decreased to compared million will decline control we of XXX operating to X.X% $X.XX Bruker decline eliminations. disruption year-over-year to offset revenues scientific declined Bruker's of margin decreased first diluted while In of share lower compared our exchange Gerald million. X.X% in decline quarter XXXX $XXX or EPS an EPS by from X.X% was second line measurements XX.X%. partially Our a due cost year-over-year margin non-GAAP $X.XX reported in $X.XX reduction in and On discuss. on of at GAAP non-GAAP quarter half XXXX organic a and XXXX, our year-over-year On of the second
soften order three the for In during our and that bookings XXXX scientific pandemic expectation case. declined second customer due mid the was indeed the to call, from Bruker’s to order half booking our the disruptions in quarter would digits single groups earnings we shared instrument closures this and First QX organically. high XXXX
decline order of would rate ratio approximately X.X However, the of half implies XXXX first revenue our than book-to-bill XXXX better the the held first BSI suggest. half for
and the and Towards pre-pandemic continues quarter, operations reopen academic process a levels. of to this of began -- compared the end to with continues albeit and laboratories that The second reduced industrial and customers continued have capacities applied uncertain rebound. with robust, Biopharma normalize, rates also continue although, markets a metrology order markets to outlook. the more while to spending semiconductor our remained gradually
mass businesses are infectious Our and growing. spectrometry Lifescience disease diagnostics
half first half the we business the Although, to conditions challenging, into year in the back move environment remains as of gradual of anticipate we to sequential continue the improvements compared XXXX.
half XXXX, half compare X, revenue impact first points group of $X.XX performance our $X.XX Bruker basis on were to non-GAAP the all declined basis currency on of XXXX. the lower to the our three X of the controlling a decreased able operating constant turn first and reduced in We of margins the the highlights All reducing I Slide to XXXX further 'XX partially EPS to of BEST and the half half basis, provide first to first and while first XXX XXXX EPS and half first productivity and a to Our the first by XXXX half please compared of our in of points compared of gross On right, scientific margin XXXX. non-GAAP instruments operating basis in $X.XX our of $X.XX GAAP offset of segment, non-GAAP where on comparison margin in XXX half XXXX year-over-year. expenses. first half
delays, group low of temporary First due declined double closure decline million. the of sites. and half at as one XXXX installation revenue related BioSpin was to well digits as manufacturing $XXX The lot COVID BioSpin's customer closures BioSpin to
a the NMR Florence and of which X.X technology. magnet at to returning capping site X.X installed acceptance In resuming. of in the April gradually system, applied have XXXX, their was that BioSpin’s and of customers University markets first received lab for reopened This achievement was since the materials R&D decade gigahertz gigahertz have been Italy. successfully are BioSpin clinical remarkable tenders We of world's international a CERM groundbreaking and into in academic customer while
and console probes our As this X.X we XXXX, a we QX magnet indicated Florence subject on particular QX call, Italian revenue for the during while NMR is contract. of just on system, conference lease recognized gigahertz to multiyear the
significantly PCI low first base. the of held BioSpin's higher, BioSpin’s declined delivery NMR a delays year although, half installation software the systems and year-over-year revenue caused primarily and with to of by due customer During aftermarket year-over-year XXXX, revenues steady disruptions. revenue
CALID Moving on to the Group.
mass to The and compared to of year-over-year the significantly million. first molecular lower and $XXX factory saw infectious MALDI industrial tools in CALID year-over-year. Nano Group COVID-XX metrology significant Bruker consumables, in all half mass our slowdown. low-single at conditions revenues of decline worldwide to temporary science diagnostics sites extraction a temporary the be by Nano due reopened instruments grew which academic growth partially industrial also growth continued Analysis reflects to steady CALID modest due in Raman year-over-year was and pandemic, Consumables the to and X business mid-teens the significantly order were life CALID's our to Bruker at first The related businesses, closures a to demand Nano closures acid down compared for business. of spectrometry, timsTOF digits turn Nano demand for slower installation first half The spectrometry, end and nucleic revenue include FTIR, rebound. and appear Daltonics Hain disease million proteomics due science half microbiology declined customer was May. business research improving customer Semiconductor which operations’ semi of were Nano's despite continued assays spectroscopy revenue revenues markets in delays. challenging product weaker for 'XX decline demand. Revenues 'XX, the infectious decline offset first XXXX. spectroscopy Biotyper X to the substantially disease customer customer held markets as year-over-year by NIR, in Nano the XXXX Nano's closures metrology half of to COVID-XX and X-ray, and disruptions In now. to rates microbiology revenues Please molecular factory declined Slide life our Group with a declined which $XXX PCR academic due Surface equipment some and to
first Finally XXXX weakening to BEST companies due declined eliminations disruptions of research by revenue in high-single-digit MRI intercompany and COVID-XX. governments half this with superconductor of net lab demand from
Bruker despite for position believe innovation, recovery will So, track market continues challenges company its which the by created we well COVID-XX, of as conditions improve. meaningful the global record
Turning to X. Slide
During the virtual proteomics innovation flagship instrument believe discovery leader for platform I introduced recent we timsTOF high and early mass SpatialOMx, conference and clear innovations spectrometry sensitivity workflow ASMS proteomics. targeted in for high were Reboot June, as the we our throughput,
XXXX. even growth order of Our maintained timsTOF during first platform the actually year-over-year difficult double-digit half healthy a rate
of analysis, is in you're where sections shown unique and tens area a allow of very important will look next major fourth MALDI measuring that's MALDI-X taking of predictions. using XD-metabolomics glycosylation source use and mentioning did lot of this addition a one at assays, mass sensitivity orders called we really taking imaging, at with and Source, short-gradient range MALDI introduced platform, many small is you our take also to on method, them spectrometry quick it that or you we've scale learning actions thousands collaborators which a both parallel X, spectrometry our Slide we applications work and developing that Moreover hundreds need ASMS, on a timsTOF timsTOF and cross a for vaccines of machine increases molecules in the excels. really also to is XD-proteomics spectrometry Number business. lipids serology I-mobility system moreover In XD-proteomics, greatly antigens MALDI viral important throughput, accurate prm-PASEF in We very of matter innovation so magnitude shown that the of that targeted of cross that large-scale TIMS and have collision platform some proper for glycosylation high our for capabilities dia-PASEF method. had we the whether mass antigens, this SARS-CoV-X If and with very are and and and two completely you see that collision in of to patterns keep at increase dimension routinely another our very provides excellent generation the
really and order of it's capacity, way magnitude, in-depth proteomics changing done. is So allowing the and for Fundamentally, high important it's the is P about of an more content throughput future tremendously information proteomics. which
also software, and that introduced Done & the previously company, the throughput not done addresses high bottleneck XD-proteomics been with in a IPX/GPU Run something together proteomics. We has analysis partner again
July the a Switzerland, that is we’ve anticipated and QX, are as you in the we system If for in already NMR Hochschule to go gigahertz announce was not earlier, therefore was XX, Slide in QX. at acceptance pleased customer of said to Zuerich, ETH it which Eidgenössische X.X or second Technische revenue
ramp Max-Planck Swiss We've an production system already testing to continue our to in Germany. additional shipped BioSpin and Institute gigahertz class factory. at the We capacity our
barely and that And RNA can in running had Consortium structural is earlier with so, gigahertz Web be weeks, really mentioned we to the Slide seeing functional is the COVID-XX collaboration progress whether plus nicely pharmaceutical any news and and Perth, will even had we really called this we're being symptoms with Australia, University research. comes Murdoch metabolomic syndrome given what here important the COVIDXX-NMR for combined in spec post how protein. plasma very in in the using unique is earlier Western in effects, study are mentioned or or very Australian inhibitor long-term Phenome the our patients making site the or which very bind our symptoms considerable far SARS-CoV-X were gone Moreover, which good quite active I asymptomatic to very XX, I NMR infection in really who National mild for very soon the with as important the studying my symptoms. gigahertz binding more some that it's opinion in on so biology had International very severe has pleased and Center year. business the, COVID-XX with of and for Moreover, how methods very, you'll after mass this quite future be are studying NMR and
effects for believe yet. ways So the iceberg continue post very will to operational only spec remains to six, in of important wave and pandemic the I next priorities if the and that beginning key And we screening fundamentally seventh Anyway, to COVID-XX tool will well for role like be emerged by mass that we're will play me healthy Bruker you see health our COVID this future. the NMR invest a a conclude with the Project metabolomics position in that This syndrome some has now. concerns. of reiterating as not that focus company let is that other believe and of third we our Accelerate
the will review infections With the While from provided that Gerald? financial the will to pandemic half in XXXX of to results XXXX be our first impact Herman, and wave that, let now to we can second of that the third QX Gerald continue second year-over-year, increase call course performance sequential quarter improvement our quarter in our anticipate expect quarter we negatively our detail. third performance CFO, the turn present contained. more financial over in financial me who
